The Aveo Oncology (NASDAQ: AVEO) saga took yet another turn today as the Securities and Exchange Commission has come knocking at the cancer drug maker’s door. According to regulatory filings, the SEC has subpoenaed the Cambridge, MA-based biotech—the latest domino to fall since the company’s disastrous results before an FDA panel on May 2. The filing says that last week, the SEC asked Aveo for “documents and information” regarding tivozanib, the cancer drug shot down by an advisory panel in May and later rejected by the FDA.